World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 84 14977 14100 7570 7008 1107 29790

Partow Kebriaei publications per year

The chart shows the history of publications by Partow Kebriaei between 1992 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Partow Kebriaei published across 35 years, from 1992 to 2026, averaging 32.3 papers a year. Output peaked at 180 publications in 2023. 79 of the 1,130 publications appeared in the last two years.

No. of publications
50 100 150
Bar chart. Horizontal axis: year, 1992 to 2026. Vertical axis: number of publications, 0 to 180. Peak 180 publications in 2023. 1992: 1 publication 1993: 0 publications 1994: 1 publication 1995: 1 publication 1996: 0 publications 1997: 0 publications 1998: 0 publications 1999: 0 publications 2000: 1 publication 2001: 0 publications 2002: 1 publication 2003: 3 publications 2004: 4 publications 2005: 14 publications 2006: 16 publications 2007: 27 publications 2008: 30 publications 2009: 40 publications 2010: 27 publications 2011: 39 publications 2012: 34 publications 2013: 46 publications 2014: 43 publications 2015: 41 publications 2016: 44 publications 2017: 48 publications 2018: 42 publications 2019: 56 publications 2020: 76 publications 2021: 76 publications 2022: 73 publications 2023: 180 publications 2024: 87 publications 2025: 77 publications 2026: 2 publications
1992 2026

1,130 publications in total across all disciplines

View publications per year as a table
Partow Kebriaei: publications per year, 1992 to 2026
Year Publications
1992 1
1993 0
1994 1
1995 1
1996 0
1997 0
1998 0
1999 0
2000 1
2001 0
2002 1
2003 3
2004 4
2005 14
2006 16
2007 27
2008 30
2009 40
2010 27
2011 39
2012 34
2013 46
2014 43
2015 41
2016 44
2017 48
2018 42
2019 56
2020 76
2021 76
2022 73
2023 180
2024 87
2025 77
2026 2
Total 1,130
Download as CSV

Partow Kebriaei publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Partow Kebriaei sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 1,101–1,120 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 1,107 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54 1,107
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Partow Kebriaei D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Partow Kebriaei sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 84–85 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003 84
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Partow Kebriaei is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, with a significant concentration in hematology and oncology. Additional areas of study include public health, environmental and occupational health, molecular biology, and genetics.

The scientist's work covers a range of key topics, notably:

  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • CAR-T cell therapy research
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Chronic Lymphocytic Leukemia Research

Among Partow Kebriaei's recent publications are:

  • "Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors," 2020, New England Journal of Medicine
  • "Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial," 2024, Nature Medicine
  • "Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma," 2021, Blood
  • "Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma," 2020, Blood Advances
  • "Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial," 2023, Nature Medicine

Frequent coauthors collaborating with Partow Kebriaei include:

  • Elizabeth J. Shpall
  • Richard E. Champlin
  • Muzaffar H. Qazilbash
  • Samer A. Srour
  • Uday Popat

Kebriaei's work is often published in academic journals such as:

  • Blood
  • Transplantation and Cellular Therapy
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • American Journal of Hematology

The scientist's research includes over 900 publications in the broad field of medicine, with more than 400 focused on hematology. Contributions to oncology and public health studies also form a substantial part of their scholarly output.

Best Publications

  • Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Sattva S. Neelapu;Sudhakar Tummala;Partow Kebriaei;William Wierda

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Enli Liu;David Marin;Pinaki Banerjee;Homer A. Macapinlac

  • Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex

    David L. Rimm;Erika R. Koslov;Partow Kebriaei;Carol D. Cianci

  • A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

    Hiroki Torikai;Andreas Reik;Pei Qi Liu;Yuanyue Zhou

  • Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

    Ann M. Leen;Catherine M. Bollard;Adam M. Mendizabal;Elizabeth J. Shpall

  • Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease

    Partow Kebriaei;Luis Isola;Erkut Bahceci;Kent Holland

  • Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

    Partow Kebriaei;Harjeet Singh;M. Helen Huls;Matthew J. Figliola

  • Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

    Marcos J.G. de Lima;Ian McNiece;Simon N. Robinson;Mark Munsell

  • Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

    Lenka V. Hurton;Lenka V. Hurton;Harjeet Singh;Amer M. Najjar;Kirsten C. Switzer

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

    Farhad Ravandi;Susan O'Brien;Deborah Thomas;Stefan Faderl

  • Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

    Hiroki Torikai;Andreas Reik;Frank Soldner;Edus H. Warren

  • Results of Inotuzumab Ozogamicin, a CD22 Monoclonal Antibody in Refractory and Relapsed Acute Lymphocytic Leukemia

    Hagop Kantarjian;Deborah Thomas;Jeffrey Jorgensen;Partow Kebriaei

  • Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

    Stefan Octavian Ciurea;Victor Eduardo Mulanovich;Rima M Saliba;Ulas D. Bayraktar

  • Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

    Antonio Di Stasi;Denái R. Milton;L.M. Poon;Amir Hamdi

  • Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

    Farhad Ravandi;Jeffrey L. Jorgensen;Deborah A. Thomas;Susan O'Brien

  • Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

    Farhad Ravandi;Susan M. O'Brien;Jorge E. Cortes;Deborah M. Thomas

  • Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

    Elias Jabbour;Sergio Giralt;Hagop Kantarjian;Guillermo Garcia-Manero

  • Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies

    Harjeet Singh;Matthew J. Figliola;Margaret J. Dawson;Helen Huls

  • Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD

    P.J. Martin;J.P. Uberti;R.J. Soiffer;H. Klingemann

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Borje S. Andersson
Borje S. Andersson The University of Texas MD Anderson Cancer Center
Marcos de Lima
Marcos de Lima The Ohio State University
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Katayoun Rezvani
Katayoun Rezvani The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine but want additional pathways or flexibility, there are several online degrees and certifications that can open doors to rewarding healthcare careers. These programs offer opportunities both for entry-level positions and for professionals seeking to advance in the field.

For those interested in pharmaceuticals, a pharmacy degree online can lead to diverse careers in clinical, retail, or research settings. This route can be especially valuable for students requiring a flexible schedule.

Another in-demand specialization is Health Information Management. Earning a him degree online allows you to work in managing medical records, data privacy, and hospital information systems.

Medical billing and coding offer a non-clinical yet vital role in healthcare administration. Discover more about medical billing and coding certification cost and how affordable it can be to get certified quickly and start working from anywhere.

Aspiring advanced practice nurses can benefit from the cheapest nurse practitioner programs that provide both affordability and convenience for working professionals.

Whether your passion leads you to clinical care, healthcare administration, or technology, these online programs offer accessible routes to enter and progress in the medical field.

Best Scientists Citing Partow Kebriaei

Trending Scientists

Recently Published Articles